We won't make an acquisition just because we have to: Piramal Pharma chief

In a Q&A, Nandini Piramal, chairperson of the firm, says the company currently sees great scope in expanding and organically growing the OTC business, and wants to build more consumer focused brands

Piramal Pharma (PPL) listed on the Indian stock exchanges on Wednesday. In October 2021, the board of Piramal Enterprises had approved the demerger of the pharmaceutical business and simplification of the corporate structure. In an interview with Sohini Das, PPL chairperson Nandini Piramal outlines her future plans for the pharma entity. Edited excerpts.

How will the demerger unlock value? Has any more restructuring been planned?

Investors, shareholders were saying that it’s very difficult to understand both financial services and pharmaceuticals. The risk-reward understanding for those folks was getting very difficult. In 2020, we raised money from Carlyle and that put